Other Events ·
KALA BIO, Inc. received a Staff Determination Letter from Nasdaq on August 27, 2026, notifying the company that its…
KALAKALA BIO, Inc.
KALA BIO, Inc. received a Staff Determination Letter from Nasdaq on August 27, 2026, notifying the company that its common stock has failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days ending August 26, 2026. Because KALA BIO effected a 1-for-50 reverse stock split on May 11, 2026, it is ineligible for the standard 180-day compliance period. The company intends to request a hearing before the Nasdaq Hearings Panel to appeal this determination, which would stay any suspension or delisting action pending the outcome. There is no assurance that the request will be granted or that the company can regain compliance. KALA BIO operates in the biotechnology industry, focusing on drug discovery and development.